Whether immunostimulants are effective in susceptible children suffering from recurrent respiratory tract infections: a modeling analysis based on literature aggregate data

Immunostimulants are gradually being used in the prevention and treatment of recurrent respiratory tract infections in susceptible children, but their drug effects have not been quantified. The purpose of this study was to confirm the efficacy of immunostimulants in the prevention and treatment of recurrent respiratory tract infections in susceptible children. A model-based meta-analysis (MBMA) was used to describe the time course of placebo and immunostimulants in the prevention of respiratory tract infections in children. The cumulative number of respiratory tract infections was used as an indicator of efficacy. A meta-analysis was used to analyze the incidence of drug-related adverse events. Fourteen articles with 2,400 pediatric subjects were finally included in the analysis. The results showed that the cumulative number of respiratory tract infections increased linearly with time, with the incidence of respiratory tract infections in the placebo group being 0.65 (95% CI: 0.55, 0.75) per month. OM-85 BV and pidotimod reduced the incidence of respiratory tract infections by 0.21 (95% CI: 0.16, 0.26) and 0.19 (95% CI: 0.17, 0.21) compared to placebo per month, respectively. Pidotimod and OM-85 BV can effectively reduce the incidence of respiratory tract infections in susceptible children, with no significant increase in the incidence of drug-related adverse events when compared with placebo [RR values were 1.07 (95% CI: 0.66, 1.71) and 1.31 (95% CI: 0.54, 3.19), respectively]. This study provides quantitative support for the application of immunostimulants for the prevention of recurrent respiratory tract infections in children. This article is protected by copyright. All rights reserved.